Novartis Executive and Leadership Team

Waseephol Vuthiparum, the Chief Financial Officer, Country at Novartis, directs all fiscal planning and resource allocation within the designated national market. This leadership role involves managing complex budgetary frameworks to support the development of innovative medications. By overseeing financial reporting and compliance, the Chief Financial Officer, Country ensures alignment with the broader corporate strategy of the pharmaceutical manufacturer. Waseephol Vuthiparum maintains strict control over capital expenditures, enabling the organization to sustain its research and development initiatives effectively. Through precise economic forecasting and risk assessment, the executive optimizes operational efficiency across the region. This financial stewardship supports the overarching mission of improving patient outcomes by securing the necessary funding for critical healthcare solutions. Ultimately, the executive drives long-term fiscal stability while navigating the unique regulatory and economic landscapes inherent to the pharmaceutical industry.

Irfan Parkar, the Chief Financial Officer, Levant at Novartis, manages the financial health and strategic investment portfolio across the Levant region. This role requires the Chief Financial Officer, Levant to oversee regional revenue streams and ensure the efficient distribution of resources for pharmaceutical production. By analyzing market trends and economic indicators, Parkar facilitates the expansion of healthcare solutions throughout the territory. Irfan Parkar coordinates with global leadership to maintain fiscal transparency and adherence to international accounting standards. The executive monitors operational costs to maximize the impact of research and development investments. Through rigorous financial oversight, the executive supports the company's goal of delivering high-quality medications to diverse patient populations. This position involves balancing immediate operational needs with the long-term growth objectives of the organization. Consequently, the executive secures the financial foundation necessary for sustained innovation and market competitiveness.

Melissa McKerracher, the Chief Financial Officer, Novartis (US) at Novartis, directs the financial strategy and capital management for the company's largest market. This role requires the Chief Financial Officer, Novartis (US) to oversee multi-billion dollar budgets dedicated to the research, development, and distribution of innovative medications. By managing financial risk and ensuring regulatory compliance, McKerracher supports the organization's commitment to delivering advanced healthcare solutions to patients across North America. Melissa McKerracher collaborates with the executive board to allocate resources toward high-impact therapeutic areas. The executive monitors market performance and economic shifts to maintain the company's competitive edge in the pharmaceutical sector. Through strategic financial planning, the executive ensures that the US operations remain profitable while funding the next generation of medical breakthroughs. This leadership position involves balancing complex fiscal requirements with the urgent need for rapid innovation in the highly competitive American healthcare landscape.

Ayman Al Mazloum, the President, Country (Saudi Arabia) at Novartis, directs all business operations and strategic growth initiatives within the Saudi Arabian market. This role requires the President, Country (Saudi Arabia) to oversee the distribution of pharmaceutical products and the implementation of healthcare programs tailored to regional needs. By managing local partnerships and regulatory relationships, Al Mazloum ensures the company's continued success in the Middle East. Ayman Al Mazloum coordinates with global leadership to align regional activities with the company's mission of improving patient outcomes. The executive drives the expansion of the company's therapeutic footprint by identifying new market opportunities and addressing unmet medical needs. Through effective leadership and operational oversight, the executive strengthens the company's presence in the region. This position involves navigating the unique cultural and regulatory landscape of Saudi Arabia to deliver innovative medications to a growing patient population.

Amir Abdelaziz, the President, Country Novartis (Saudi Arabia) at Novartis, manages the overall corporate strategy and operational execution for the company's operations in Saudi Arabia. This role involves leading the local team in the delivery of innovative pharmaceutical solutions and ensuring compliance with national healthcare standards. By overseeing the commercial and medical affairs functions, Abdelaziz drives the company's mission to improve patient health across the region. Amir Abdelaziz fosters strategic collaborations with local healthcare stakeholders to enhance the accessibility of advanced treatments. The executive monitors market performance and adapts operational plans to meet the evolving needs of the Saudi Arabian healthcare system. Through strong leadership and a focus on scientific excellence, the executive ensures that the company remains a trusted partner in the region. This position requires a deep understanding of the local market dynamics to effectively scale the company's impact and support long-term growth.

Osamu Ida, the Regional Chief Marketing Officer, Head Patient Safety Quality Assurance , Ps Quality Assurance Regions & Countries, Gdd Quality Assurance (Region Japan) at Novartis, architects comprehensive marketing strategies while ensuring the highest standards of patient safety and quality assurance. This multifaceted role requires the Regional Chief Marketing Officer, Head Patient Safety Quality Assurance , Ps Quality Assurance Regions & Countries, Gdd Quality Assurance (Region Japan) to oversee the integration of clinical data into commercial messaging. By directing quality assurance protocols across the Japanese market, Ida maintains compliance with stringent pharmaceutical regulations. Osamu Ida coordinates with research teams to validate the efficacy and safety of new treatments before market entry. The executive drives the adoption of innovative healthcare solutions by aligning marketing initiatives with patient-centric outcomes. Through this dual focus on commercial growth and rigorous safety oversight, the executive strengthens the company's reputation for reliability and scientific integrity in the region.

Evelyn Messer, the Senior Meeting Planner, Chief Revenue Officer Management . at Novartis, coordinates high-level strategic engagements and operational logistics for the executive leadership team. This role involves managing the complex scheduling and communication workflows that support the Chief Revenue Officer in driving global sales performance. By facilitating critical meetings and stakeholder interactions, Messer ensures that the revenue management team remains focused on core business objectives. Evelyn Messer optimizes the flow of information between departments to accelerate decision-making processes regarding pharmaceutical product launches. The executive manages the logistical requirements for international conferences and internal strategy sessions, ensuring that all activities align with the company's mission of improving patient health. Through meticulous planning and organizational support, the executive enhances the productivity of the revenue management function. This leadership role directly contributes to the efficiency of the commercial operations team by streamlining executive communication and strategic planning efforts.

Prateek Gaur, the Chief of Staff, Medical Affairs at Novartis, manages the operational workflows and strategic initiatives within the medical affairs division. This role requires the Chief of Staff, Medical Affairs to coordinate between clinical research teams and commercial leadership to ensure the effective communication of scientific data. By overseeing internal processes, Gaur facilitates the rapid dissemination of medical insights regarding new pharmaceutical treatments. Prateek Gaur aligns the medical affairs agenda with the company's broader mission of improving patient outcomes through evidence-based medicine. The executive manages cross-functional projects that bridge the gap between laboratory research and real-world clinical application. Through rigorous project management and stakeholder engagement, the executive optimizes the efficiency of the medical affairs team. This position involves navigating complex scientific and regulatory environments to support the successful launch and adoption of innovative healthcare solutions across global markets.

Soukaïna Mouallif, the Customer Engagement Chief of Staff (US) at Novartis, directs the operational strategy for customer-facing initiatives within the United States. This role involves coordinating the efforts of sales, marketing, and medical teams to ensure a cohesive approach to patient and provider engagement. By overseeing the implementation of customer-centric programs, Mouallif drives the adoption of innovative pharmaceutical solutions. Soukaïna Mouallif manages the internal communication channels that keep the US commercial team aligned with the company's global mission. The executive analyzes customer feedback and market data to refine engagement strategies and improve patient outcomes. Through effective project management and cross-departmental collaboration, the executive ensures that the company maintains strong relationships with healthcare providers. This leadership role focuses on optimizing the customer experience to support the long-term growth and market penetration of the company's diverse portfolio of medications.

Daniela Castaneda, the Immunology Director, Commercial Operations & Chief of Staff at Novartis, oversees the commercial strategy for the immunology portfolio while managing operational workflows for the leadership team. This role requires the Immunology Director, Commercial Operations & Chief of Staff to drive the market success of treatments for complex immune-related conditions. By coordinating commercial operations, Castaneda ensures that the company effectively reaches patients in need of specialized care. Daniela Castaneda aligns the immunology division's goals with the broader corporate mission of scientific innovation. The executive manages the integration of clinical insights into commercial plans to maximize the impact of the immunology product line. Through strategic oversight and operational excellence, the executive supports the growth of the company's therapeutic offerings. This position involves balancing the demands of commercial expansion with the rigorous requirements of medical affairs to ensure that patients receive the most effective healthcare solutions available.